Being a professional financial planner requires more than just being good with numbers. Today’s advisors must develop skills that can help them build personal ties with clients, understand their needs and create a strategy to help families pursue their goals.
Eager to produce “job ready” graduates, many universities and colleges are teaching the real world skills young advisors need in the workplace. And to help more schools take their programs to the next level, TD Ameritrade Institutional1 has awarded its third annual Next Gen Financial Planning Grants: a $50,000 grant to the University of North Texas in Denton, Texas, to expand an existing financial planning degree program, and $25,000 to Temple University in Philadelphia to foster development of a new program.
To view the multimedia news release visit
http://www.multivu.com/players/English/7559051-td-ameritrade-scholarship-winners/
Today, the Crohn’s & Colitis Foundation of America (CCFA) unveiled its newest fundraising and endurance initiative, spin4 crohn’s & colitis cures, an indoor cycling event that will raise funds for research, awareness, and patient services. The inaugural event will take place on December 5th at local studios and fitness centers in New York, Los Angeles, and Chicago as part of Crohn’s and Colitis Awareness Week.
“We’re eager to create a movement by launching spin4 crohn’s & colitis curesacross the country on December 5,” said Craig Comins, vice president of CCFA’s Team Challenge program. “It’s about motivating advocates to contribute to the IBD community and take research to the next level. We welcome all ages and athletic abilities to join us with one united voice to spin4 cures.”
Individuals form teams of up to four people per bike and participate in a two-hour indoor cycling relay. Alternatively, solo riders can take on the entire two-hours themselves. No matter the size of the team, each bike has a $1,000 fundraising commitment for CCFA. Professional instructors will lead teams to high-energy music offering a lively workout experience. The event is capped off with a cocktail hour to reward participants for their efforts in the stationary bike relay and fundraising success.
To view the multimedia news release visit
http://www.multivu.com/players/English/7512651-ccfa-spin4-crohns-colitis-cures/
Pilot Corporation of America (Pilot Pen) is encouraging parents and students to help erase bullying this school year through their ‘Erase Bullying for Good’ campaign. This campaign was developed in partnership with STOMP Out Bullying, the leading bullying prevention organization in the U.S. The ‘Erase Bullying for Good’ campaign is funded with proceeds from sales of Pilot’s FriXion Clicker erasable gel ink pen, a revolutionary kind of erasable pen that enables students to enjoy mistake-free writing. A total of $125,000 will be donated to STOMP Out Bullying for the educational and support programs they offer parents, students and educators designed to transform and prevent negative bullying behaviors in U.S. schools.
Bullying has become a real problem in U.S. schools and Pilot Pen wanted to help be part of the solution. “There are a lot of parents that work at Pilot, and we are well aware of the challenges facing kids today. We wanted to help address the issue of bullying at a national level by supporting STOMP Out Bullying. They are the ideal resource & partner, with their educational programs and confidential help chat line for teens,” said Ariann Langsam, Director of Marketing at Pilot Corporation of America.
To view the multimedia release go to:
http://www.multivu.com/players/English/7564451-pilot-pen-erase-bullying/
Bringing developers advanced integration, scalability and peripherals all in one chip, Texas Instruments (TI) (NASDAQ: TXN) today announced the Sitara™ AM57x processor family, the highest performance devices in this processor platform. Sitara AM57x processors are designed for a broad range of embedded and industrial applications through their unique heterogeneous architecture including ARM® Cortex®-A15 cores for high-performance processing and running a high-level operating system (HLOS). Additionally, AM57x processors integrate TI’s C66x digital signal processors (DSPs) for analytics and real-time computation, programmable real-time units (PRU) and ARM Cortex-M4 cores for control functions, and video and graphic accelerators for advanced user interfaces and multimedia applications, making the AM57x processors unmatched in their class.
The new Sitara AM57x family of processors was designed from the ground up with high performance and integration in mind. As a result, the processors bring developers unparalleled performance of more than 40 percent greater than quad-core ARM Cortex-A9 processors and 280 percent greater than standard dual-core ARM Cortex-A9 processors found in the broad embedded market.
To view the multimedia release go to:
http://www.multivu.com/players/English/70647530-ti-sitara-am57x-processor/
At Munich’s real estate exhibition last week, Russia’s leading e-commerce company, Ulmart, hosted a “working breakfast” to discuss the nuances and intricacies of investing in Russia today during times of heightened international tension.
The topic, “Making the Case for Star Investment Projects in Russia”, featured Ulmart’s chairman and majority shareholder Dmitry Kostygin; Andrew Kaye, Managing Director and Co-Head of Technology Banking, William Blair International; Calin Anton Business Development Director Russia & CIS, Astron; and, Tim Millard, Regional Director, Head of Consulting Services at Jones Lang LaSalle, Russia.
A lively discussion kicked off about how some in the investment community tend to focus—even obsess—on macro realties at a state-to-state level ignoring many truly interesting project; precisely the types of projects that keep most of the world’s economies developing positively from cycle to cycle.
To view the multimedia release go to:
http://www.multivu.com/players/English/7660751-ulmart-russian-investment-update/
At Munich’s real estate exhibition last week, Russia’s leading e-commerce company, Ulmart, hosted a “working breakfast” to discuss the nuances and intricacies of investing in Russia today during times of heightened international tension.
The topic, “Making the Case for Star Investment Projects in Russia”, featured Ulmart’s chairman and majority shareholder Dmitry Kostygin; Andrew Kaye, Managing Director and Co-Head of Technology Banking, William Blair International; Calin Anton Business Development Director Russia & CIS, Astron; and, Tim Millard, Regional Director, Head of Consulting Services at Jones Lang LaSalle, Russia.
A lively discussion kicked off about how some in the investment community tend to focus—even obsess—on macro realties at a state-to-state level ignoring many truly interesting project; precisely the types of projects that keep most of the world’s economies developing positively from cycle to cycle.
To view the multimedia release go to:
http://www.multivu.com/players/English/7660751-ulmart-russian-investment-update/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
Leveraging advanced skincare science inspired by the Nobel Prize-winning discovery of Aquaporins, the Artistry Hydra-V™ collection presents a new level of skincare targeting deep hydration. This comprehensive line provides up to 24-hour hydration for skin that feels soft, smooth and supple.
Whatever level of hydration skin needs, the Artistry Hydra-V™ line answers with a range of formulas that can be customized to skin type, season and climate. “Artistry Hydra-V™ products are for the younger consumer who is not yet concerned with the signs of aging but instead want skincare products to give her a beautiful, healthy complexion. This advancement in skincare technology epitomizes the Artistry® Forward Beauty platform and meets the balanced hydration needs of women younger than 35,” says Jackie Nickel, Chief Marketing Officer for the Americas Region. “It’s our first collection to focus on deep hydration for all skin types.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7488157-amway-artistry-hydra-v/
Kia Motors America (KMA) today unveiled the all-new 2017 Sportage at the Los Angeles Auto Show. The fourth-generation Sportage, KMA’s longest-running nameplate, wraps stunning contemporary design around a structure that is both stiffer and more spacious than before. Advanced driver assistance technologies, significant suspension and steering improvements, and available intelligent AWD vastly improve the Sportage’s driving dynamics while premium materials and world-class craftsmanship create a class-up experience in an otherwise utilitarian segment.
“Simply put, the Sportage is a breed apart in the compact CUV segment,” said Orth Hedrick, vice president, product planning KMA. “Instead of bland utility, the Sportage combines distinctly European and sporty styling with thoughtful design and functionality, including innovative packaging, premium materials, a turbocharged engine and surprising features. Sales of compact CUVs are on a sharply upward trajectory, and the all-new 2017 Sportage hits the sweet spot by providing an alternative for those seeking to express themselves with a vehicle that’s versatile enough to suit their unique lifestyle.”
The all-new Sportage’s roomier, more luxurious cabin features an impressive level of craftsmanship, with high-quality, soft-touch materials and a range of technologies improving overall comfort, convenience, and connectivity. Updates to the drivetrain provide enhanced efficiency and performance, while changes to the suspension deliver better ride and handling. Like the outgoing model, the all-new Sportage will be built at Kia’s production facility in Gwangju, Korea, and be available in three distinct trim levels (LX, EX, SX Turbo) when it goes on sale next year. Pricing will be announced closer to the Sportage’s on-sale date.
To view the multimedia release go to:
http://www.multivu.com/players/English/7436354-2017-kia-sportage-l-a-auto-show-debut/
Nearly 50 vehicles meet tougher criteria for 2016 to take home the Insurance Institute for Highway Safety’s TOP SAFETY PICK+ award, earning good ratings in all five IIHS crashworthiness evaluations and an advanced or higher rating for front crash prevention. An additional 13 models qualify for TOP SAFETY PICK.
The baseline requirements for both awards are good ratings in the small overlap front, moderate overlap front, side, roof strength and head restraint tests, as well as a standard or optional front crash prevention system. The 48 winners of the “plus” award have a superior- or advanced-rated front crash prevention system with automatic braking capabilities. These vehicles must stop or slow down without driver intervention before hitting a target in tests at 12 mph, 25 mph or both. Models with a basic-rated front crash prevention system, which typically only issues a warning and doesn’t brake, qualify for TOP SAFETY PICK.
IIHS inaugurated TOP SAFETY PICK in the 2006 model year to help consumers home in on vehicles with the best safety performance. The TOP SAFETY PICK+ accolade was introduced in 2012 to recognize vehicles that offer an advanced level of safety.
